Dominique Costagliola1. 1. aSorbonne Universités, UPMC Univ Paris 06 bINSERM, UMRS 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.
Abstract
PURPOSE OF REVIEW: To describe and understand why the HIV-infected population is aging in high-income countries, the rate and causes of death in comparison with the general population, and to illustrate the impact of combined antiretroviral therapy (cART) on life expectancy and to discuss needs for further researches. RECENT FINDINGS: The HIV-infected population is aging in high-income countries because of increasing age at HIV infection, higher risk of late diagnosis in older individuals and decrease in the AIDS-defining and non-AIDS-defining death rates. Compared with the general population, the risk of death is no longer elevated in many non-IDU-infected individuals successfully treated with cART. SUMMARY: Further researches are needed to reconcile the absence of increased mortality risk in HIV-infected individuals with controlled viral load and restored immunity with the observed higher risk of comorbidities, such as cardiovascular diseases and non-AIDS-defining cancers, and the accelerated aging hypothesis, in particular, to help stratify HIV individuals who are at risk; to define the optimal management of multimorbidity and polypharmacy, even in the absence of a higher comorbidity risk; and to better account for increased life expectancy and multimorbidity burden to plan the future needs in care for HIV-infected individuals.
PURPOSE OF REVIEW: To describe and understand why the HIV-infected population is aging in high-income countries, the rate and causes of death in comparison with the general population, and to illustrate the impact of combined antiretroviral therapy (cART) on life expectancy and to discuss needs for further researches. RECENT FINDINGS: The HIV-infected population is aging in high-income countries because of increasing age at HIV infection, higher risk of late diagnosis in older individuals and decrease in the AIDS-defining and non-AIDS-defining death rates. Compared with the general population, the risk of death is no longer elevated in many non-IDU-infected individuals successfully treated with cART. SUMMARY: Further researches are needed to reconcile the absence of increased mortality risk in HIV-infected individuals with controlled viral load and restored immunity with the observed higher risk of comorbidities, such as cardiovascular diseases and non-AIDS-defining cancers, and the accelerated aging hypothesis, in particular, to help stratify HIV individuals who are at risk; to define the optimal management of multimorbidity and polypharmacy, even in the absence of a higher comorbidity risk; and to better account for increased life expectancy and multimorbidity burden to plan the future needs in care for HIV-infected individuals.
Authors: Rainer Puhr; Nagalingeswaran Kumarasamy; Penh Sun Ly; Oon Tek Ng; Kinh Van Nguyen; Tuti Parwati Merati; Thuy Thanh Pham; Man Po Lee; Jun Yong Choi; Jeremy L Ross; Matthew G Law Journal: J Acquir Immune Defic Syndr Date: 2017-04-15 Impact factor: 3.731
Authors: Markella V Zanni; Kathleen Fitch; Corinne Rivard; Laura Sanchez; Pamela S Douglas; Steven Grinspoon; Laura Smeaton; Judith S Currier; Sara E Looby Journal: HIV Clin Trials Date: 2017-03
Authors: A Calcagno; S Nozza; C Muss; B M Celesia; F Carli; S Piconi; G V De Socio; A M Cattelan; G Orofino; D Ripamonti; A Riva; G Di Perri Journal: Infection Date: 2015-05-19 Impact factor: 3.553
Authors: Sara Lodi; Dominique Costagliola; Caroline Sabin; Julia Del Amo; Roger Logan; Sophie Abgrall; Peter Reiss; Ard van Sighem; Sophie Jose; Jose-Ramon Blanco; Victoria Hernando; Heiner C Bucher; Helen Kovari; Ferran Segura; Juan Ambrosioni; Charalambos A Gogos; Nikos Pantazis; Francois Dabis; Marie-Anne Vandenhende; Laurence Meyer; Rémonie Seng; M John Gill; Hartmut Krentz; Andrew N Phillips; Kholoud Porter; Beatriz Grinsztejn; Antonio G Pacheco; Roberto Muga; Janet Tate; Amy Justice; Miguel A Hernán Journal: J Acquir Immune Defic Syndr Date: 2017-11-01 Impact factor: 3.731
Authors: Jeffrey V Lazarus; Kelly Safreed-Harmon; Simon E Barton; Dominique Costagliola; Nikos Dedes; Julia Del Amo Valero; Jose M Gatell; Ricardo Baptista-Leite; Luís Mendão; Kholoud Porter; Stefano Vella; Jürgen Kurt Rockstroh Journal: BMC Med Date: 2016-06-22 Impact factor: 8.775